Adult Dosing

Corticosteroid-responsive dermatoses

• Apply a thin film to the affected area(s) bid-tid; discontinue therapy when control is achieved

• Consider reassessment of diagnosis if no improvement is seen within 2 wks
• Do not use occlusive dressings

Pediatric Dosing

• Use in pediatric patients <1 yr is not recommended. Safety and effectiveness of drug use for >3 wks in pediatric patients have not been established
• 1-18 yrs
• Apply a thin film to the affected area(s) bid-tid; discontinue therapy when control is achieved

• Consider reassessment of diagnosis if no improvement is seen within 2 wks
• Do not use occlusive dressings

[Outline]

• Adult Dosing
• Pediatric Dosing

• Indicated for relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing syndrome, hyperglycemia, and glucosuria may occur due to systemic absorption of alclometasone; application of the more potent steroids over large surface areas, prolonged use, and to areas under occlusion add on to the systemic absorption. Monitor patients periodically for evidence of HPA axis suppression; discontinue or reduce the frequency of application, or substitute with a less potent steroid if HPA axis suppression is noted
• Pediatric patients may be more susceptible to systemic toxicity as proportionally larger amounts of topical corticosteroids are absorbed. Limit the use to the least amount compatible with an effective therapeutic regimen
• If concomitant dermatological infections occur, provide appropriate antifungal or antibacterial therapy; temporarily discontinue alclometasone until the infection has been adequately controlled
• Can cause local skin adverse reactions; if irritation develops, discontinue the drug and provide appropriate therapy

Cautions: Use cautiously in

• Skin infections
• Peripheral vascular disease
• Pediatric patients

Supplemental Patient Information

• Alclometasone is for external use only; avoid contact with the eyes. Advise patients not to use on the face, underarms, or groin areas unless directed by their physicians
• Advise patients not to bandage, cover or wrap the treated area(s) unless directed by their physician
• Instruct parents of pediatric patients not to use alclometasone for treating diaper dermatitis. Advise parents not to use diapers or plastic pants for a child being treated in the diaper area, as these garments may constitute occlusive dressings

Pregnancy Category:C

Breastfeeding: No studies conducted during breastfeeding; short-term application of topical corticosteroids is not expected to pose a risk to the breastfed infant by passage into breastmilk. Use of the least potent drug on the smallest area of the mother's skin is recommended. Ensure that the infant's skin does not come into direct contact with the areas treated with this drug. Use of lower potency corticosteroids and water-miscible cream products on the nipple or areola is recommended. Any topical corticosteroid should be wiped off thoroughly prior to nursing if it is applied to the nipple or areola. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 6 April 2011). Manufacturer advises caution when administered to nursing mothers.

• CNS: Intracranial hypertension (pediatric patients)
• DERM: Itching, burning, erythema, pruritus, dryness, irritation, papular rashes, erythema, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin atrophy, striae, miliaria
• ENDO: HPA axis suppression, Cushing syndrome
• METABOLIC: Hyperglycemia
• MISC: Secondary infections

• Corticosteroids; exact mechanism of anti-inflammatory action is unknown; probably acts by induction of phospholipase A2 inhibitory proteins (lipocortins). These proteins inhibit the release of their common precursor, arachidonic acid, thereby controlling the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes
• Metabolized primarily in the liver; CYP450: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Aclovate

US Availability

alclometasone (generic)

• CRE: 0.05%
• OINT: 0.05%

Aclovate

• CRE: 0.05%
• OINT: 0.05%

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Boots Pharmacy Eczema and Dermatitis Cream

UK Availability

Boots Pharmacy Eczema and Dermatitis Cream

• CRE: 0.05%

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Dermatologic

Dermatologic Topical Agents

Steroids

Pricing data from www.DrugStore.com in U.S.A.

• Aclovate 0.05 % CREA [Tube] (PHARMADERM)
  15 % = $50.99
  45 % = $140.97
• Aclovate 0.05 % CREA [Tube] (PHARMADERM)
  60 % = $85.99
  180 % = $239.96
• Aclovate 0.05 % OINT [Tube] (PHARMADERM)
  15 % = $50.99
  45 % = $129.97
• Alclometasone Dipropionate 0.05 % OINT [Tube] (FOUGERA)
  60 % = $42.99
  180 % = $119.97
• Alclometasone Dipropionate 0.05 % OINT [Tube] (FOUGERA)
  15 % = $27.99
  30 % = $45.98
• Aclovate 0.05 % CREA [Tube] (PHARMADERM)
  45 % = $73.99
  90 % = $136.97
• Alclometasone Dipropionate 0.05 % OINT [Tube] (FOUGERA)
  45 % = $35.99
  90 % = $61.97
• Aclovate 0.05 % OINT [Tube] (PHARMADERM)
  60 % = $121.99
  120 % = $235.96

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.